XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Loan Payable
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Loan Payable
9.
LOAN PAYABLE (AMOUNTS IN THOUSANDS)
On January 15, 2021,
 the Company entered into a loan agreement with a lender to borrow a term loan amount of $
35,000
to be funded in three tranches. Tranche A of $
15,000
was wired to the Company on January 15, 2021. Tranche B of $
10,000
will be available through March 31, 2022 contingent upon achievement of each of the following: i)
receipt of at least $50,000 in Series C equity capital, ii) initiation of the Phase 1 combination study of TPST-1495 or monotherapy expansion study, and iii) initiation of Phase 2 trial of TPST-1120 or the 1L Triplet Collaboration study.
And Tranche C of $
10,000
is available at lender’s option. The term loan matures on
August 1, 2025
and has an annual floating interest rate of
7.15
% which is an Index Rate plus
7
%.
Index Rate is the greater of
(i)
30-day
US LIBOR or (ii)
0.15
%. Monthly principal payments of $
500
will begin on
March 1, 2023
. Related to this borrowing, the Company paid $
96
of debt issuance costs and the amount would be amortized as additional interest expense over the life of the loan. As of June 30, 2021, the balance of the loan payable (net of debt issuance costs) was $
14,915
.
The carrying value of the loan approximates fair value.
For the three months and six months period ended June 30, 2021, total interest expense were $276 and $507, respectively.